Wednesday, April 26, 2023, San Antonio, Texas, 11:15 AM – 12:45 PM Central Time (12:15 PM – 1:45 PM Eastern Time)

What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation

Fifteenth Annual RTP Symposium Series Held During the Annual ONS Congress

Cervical and Endometrial Cancer

 
Location
Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Program Schedule — Central Time
10:45 AM – 11:15 AM — Registration
11:15 AM – 12:45 PM — Lunch Meeting

Meeting Room
Texas Ballroom (Salons A-C) – Fourth Floor


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Paula J Anastasia, MN, RN, AOCN
GYN Oncology Patient-Nurse Educator
Los Angeles, California

Michael J Birrer, MD, PhD
Vice Chancellor, UAMS
Director, Winthrop P Rockefeller Cancer Institute
Director, Cancer Service Line
Professor of Biochemistry and Molecular Biology
Director’s Endowed Chair for the Winthrop
P Rockefeller Cancer Institute
University of Arkansas for Medical Sciences
Little Rock, Arkansas


Jennifer Filipi, MSN, NP
Department of Gynecologic Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Brian M Slomovitz, MD
Professor, OB-GYN, Florida International University
Director, Gynecologic Oncology
Co-Chair, Cancer Research Committee
Mount Sinai Medical Center
Miami, Florida

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by GSK and Karyopharm Therapeutics during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26–30, 2023 in San Antonio, Texas. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
10:45 AM – 11:15 AM — Registration
11:15 AM – 12:45 PM — Educational Lunch Meeting

What I Tell My Patients About ...

The Clinical Significance of Microsatellite Instability (MSI)/Mismatch Repair Deficiency (dMMR) in Endometrial Cancer (EC)

  • Incidence of MSI-high (MSI-H)/dMMR advanced EC; implications for prognosis and treatment selection
  • Rationale for the activity of immune checkpoint inhibitors in patients with MSI-H/dMMR tumors; mechanistic similarities and differences between pembrolizumab and dostarlimab
  • Published efficacy and safety data with pembrolizumab and dostarlimab monotherapy for MSI‑H/dMMR advanced EC
  • Optimal integration of pembrolizumab and dostarlimab into the care of patients with advanced MSI‑H/dMMR EC
  • Recently presented results from Phase III studies evaluating immune checkpoint inhibitors in combination with chemotherapy as first-line treatment for advanced or recurrent EC; implications for the management of MSI-H/dMMR disease

The Management of Mismatch Repair-Proficient (pMMR) Metastatic EC

  • Biologic rationale for combining immune checkpoint inhibitors with agents targeting the VEGF pathway in EC
  • Optimal integration of pembrolizumab/lenvatinib into EC management algorithms
  • Clinical activity documented with dostarlimab monotherapy in patients with pMMR EC
  • Potential ramifications of recently presented positive results with the use of up-front anti-PD-1 antibodies combined with chemotherapy for the management of pMMR EC

The Role of Immune Checkpoint Inhibitors in the Care of Patients with Cervical Cancer (CC)

  • FDA approval of pembrolizumab/chemotherapy with or without bevacizumab and implications for patient care
  • Available data with pembrolizumab monotherapy for recurrent advanced CC; relationship between PD-L1 status and activity of pembrolizumab

Tisotumab Vedotin and Its Current Role in CC Management

  • Mechanism of action and structural components of the antibody-drug conjugate tisotumab vedotin
  • Optimal integration of tisotumab vedotin into clinical care for patients with advanced CC who experience disease progression after chemotherapy
  • Monitoring and management techniques for tisotumab vedotin-related ocular adverse events; importance of collaboration with eye care specialists

Tolerability and Other Practical Considerations with Anti-PD-1/PD-L1 Antibodies Alone or in Combination with Other Agents

  • Pathophysiology, incidence and spectrum of immune-mediated and other adverse events observed with anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other systemic therapies
  • Recommended monitoring and management for immune-related and other adverse events associated with immune checkpoint inhibitors in the treatment of gynecologic cancers
  • Role of rechallenge with immune checkpoint inhibitor therapy after treatment interruption due to immune-mediated toxicity
  • Relative and absolute contraindications to anti-PD-1/PD-L1 antibody therapy; role, if any, for patients with preexisting autoimmune conditions or a history of solid organ transplant

The Potential Benefits of Clinical Trial Participation

  • Appropriate identification of patients with EC or CC who may be candidates for clinical trial participation
  • Importance of clinical research and potential advantages of study participation for individual patients and the gynecologic cancer community
  • Strategies to dispel common misperceptions about clinical trial participation, such as concerns over safety, expense, receiving a placebo or the ability to withdraw
  • Educating interested patients about the requirements of trial participation; instructions on adherence, follow-up, adverse-event reporting, et cetera

Promising Investigational Agents and Strategies for Advanced EC and CC

  • Mechanism of antitumor activity of selinexor and biologic rationale for its investigation as maintenance therapy for EC
  • Progression-free survival advantage documented with selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent EC
  • Other promising novel agents and strategies under investigation for EC and CC

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cervical and endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand the importance of microsatellite instability (MSI) and mismatch repair (MMR) assessment in endometrial cancer, and adapt current testing practices to optimally identify patients with MSI-high or MMR-deficient disease.
  • Recognize the benefits observed with anti-PD-1/PD-L1 antibodies as monotherapy for MSI-high or MMR-deficient endometrial cancer, and integrate these agents into patient care.
  • Appreciate available research findings with anti-PD-1/PD-L1 antibodies and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer, and consider the potential role of this strategy in the care of patients with MSI-high/MMR-deficient and MMR-proficient disease.
  • Review the biologic rationale for combining anti-PD-1/PD-L1 antibodies with agents targeting the VEGF pathway, and counsel patients about the effectiveness of this novel strategy for advanced endometrial cancer that is not MSI high or MMR deficient.
  • Evaluate the efficacy and safety of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with platinum-based chemotherapy for metastatic cervical cancer, and educate patients about the benefits and risks of these approaches.
  • Describe the scientific justification for, published data with and toxicity profiles of agents and strategies under investigation for endometrial or cervical cancer, and use this information to discuss clinical trial opportunities for patients.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. https://www.researchtopractice.com/Meetings/ONS2023/Cervical-Endometrial/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Filipi has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Anastasia — Advisory Committee: Merck; Speakers Bureau: Seagen Inc. Dr Birrer — Advisory Board: AstraZeneca Pharmaceuticals LP, GSK, Mersana Therapeutics Inc. Dr Slomovitz — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, EQRx, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Incyte Corporation, Lilly, Merck, Novartis, Seagen Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from GSK and Karyopharm Therapeutics.

Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Meeting Room:
Texas Ballroom (Salons A-C) – Fourth Floor

The Grand Hyatt San Antonio is the headquarters hotel for the 2023 ONS Congress and is conveniently connected to the Henry B González Convention Center.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cervical and endometrial cancer.

​ ​ ​
IN-PERSON registration
Thank you for your interest in our NCPD program taking place in San Antonio, Texas. At this time online preregistration for in-person is closed for this event. LIMITED SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 10:45 AM Central Time on Wednesday, April 26th. If you are interested in attending, please visit our registration desk located outside the Texas Ballroom (Salons A-C) – Fourth Floor of the Grand Hyatt San Antonio River Walk hotel which is connected to the Henry B Gonzalez Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com.

Please note, onsite registration does not guarantee seating and participation in meal service and will be based on availability.

LIVE WEBCAST registration open to all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.